Symbiotec Pharmalab MD, chairman, board of directors and AGM
NSE: SYMBIOTECBSE: 544889Pharmaceuticals & Biotechnology
Last close ₹1,164.20down ₹33.30 (2.78%)BSE ₹1,164.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,197.50.
Range of traded prices from listing on 1 Sep 2026 to 23 Oct 2026
₹934.20Low, 1 Sep 2026₹1,309.90High, 16 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹7,481 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No balance sheet
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Sep 2026
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,58,23231.5% delivered
Statutory auditor
Named in the results for the quarter to Jun 2026.
- S R B C & CO LLPPeer-review certificate valid to Feb 2029
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
How money raised was used
The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it.